Allyson Parry

2.3k total citations
22 papers, 550 citations indexed

About

Allyson Parry is a scholar working on Neurology, Epidemiology and Rheumatology. According to data from OpenAlex, Allyson Parry has authored 22 papers receiving a total of 550 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Neurology, 16 papers in Epidemiology and 5 papers in Rheumatology. Recurrent topics in Allyson Parry's work include Meningioma and schwannoma management (16 papers), Neurofibromatosis and Schwannoma Cases (16 papers) and Vascular Malformations Diagnosis and Treatment (11 papers). Allyson Parry is often cited by papers focused on Meningioma and schwannoma management (16 papers), Neurofibromatosis and Schwannoma Cases (16 papers) and Vascular Malformations Diagnosis and Treatment (11 papers). Allyson Parry collaborates with scholars based in United Kingdom, Australia and Italy. Allyson Parry's co-authors include Dorothy Halliday, D. Gareth Evans, Pieter Pretorius, Sally Painter, Samuel MacKeith, Shazia Afridi, Patrick Axon, Katrina Morris, John F. Golding and Rosalie E. Ferner and has published in prestigious journals such as The Lancet Neurology, Psychopharmacology and Neurosurgery.

In The Last Decade

Allyson Parry

22 papers receiving 541 citations

Peers

Allyson Parry

NEURO

EPIDE

PFM

RHEUM

ONCOL

Charlotte Hammerbeck-Ward United Kingdom

Clare Giblin United States

Seyed H. Mousavi United States

Chris Bundell Australia

Tsutomu Hitotsumatsu Japan

Boyong Mao China

Isabel Gugel Germany

Fatih Bayraklı Türkiye

Ali Liu China

Shugan Zhu China

Charlotte Hammerbeck-Ward United Kingdom

Allyson Parry

391 ×0.9

NEURO

328 ×1.1

EPIDE

62 ×0.5

PFM

64 ×0.6

RHEUM

47 ×1.0

ONCOL

Citations per year, relative to Allyson Parry Allyson Parry (= 1×) peers Charlotte Hammerbeck-Ward

Countries citing papers authored by Allyson Parry

Since Specialization

Citations

This map shows the geographic impact of Allyson Parry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allyson Parry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allyson Parry more than expected).

Fields of papers citing papers by Allyson Parry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allyson Parry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allyson Parry. The network helps show where Allyson Parry may publish in the future.

Co-authorship network of co-authors of Allyson Parry

This figure shows the co-authorship network connecting the top 25 collaborators of Allyson Parry. A scholar is included among the top collaborators of Allyson Parry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allyson Parry. Allyson Parry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Halliday, Dorothy, et al.. (2023). Stereotactic Radiosurgery and Radiotherapy for Vestibular Schwannoma in NF2‐Related Schwannomatosis. The Laryngoscope. 134(5). 2364–2371. 1 indexed citations

Wasik, Martin, et al.. (2021). Structural Abnormalities of the Central Retina in Neurofibromatosis Type 2. Ophthalmic Research. 65(1). 77–85. 2 indexed citations

Cubbin, Sally, Laurence Leaver, & Allyson Parry. (2020). Attention deficit hyperactivity disorder in adults: common in primary care, misdiagnosed, and impairing, but highly responsive to treatment. British Journal of General Practice. 70(698). 465–466. 2 indexed citations

Halliday, Dorothy, Grace Vassallo, Karine Lascelles, et al.. (2019). Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity. Clinical Genetics. 96(2). 151–162. 15 indexed citations

Halliday, Dorothy, Allyson Parry, & D. Gareth Evans. (2019). Neurofibromatosis type 2 and related disorders. Current Opinion in Oncology. 31(6). 562–567. 11 indexed citations

Painter, Sally, et al.. (2018). Neurofibromatosis Type 2–Related Eye Disease Correlated With Genetic Severity Type. Journal of Neuro-Ophthalmology. 39(1). 44–49. 19 indexed citations

Anand, Geetha, Michael Pike, Sanjay R. Mehta, et al.. (2018). Diagnosis of sporadic neurofibromatosis type 2 in the paediatric population. Archives of Disease in Childhood. 103(5). 463–469. 17 indexed citations

May, Anne M., James D. Ramsden, C. Oliver Hanemann, et al.. (2018). Progression of hearing loss in neurofibromatosis type 2 according to genetic severity. The Laryngoscope. 129(4). 974–980. 19 indexed citations

Browne, Kath, et al.. (2018). First report of the efficacy of vestibular rehabilitation in improving function in patients with Neurofibromatosis type 2: an observational cohort study in a clinical setting. Disability and Rehabilitation. 41(14). 1632–1638. 4 indexed citations

10.

King, Andrew T., Scott Rutherford, Charlotte Hammerbeck-Ward, et al.. (2017). Malignant Peripheral Nerve Sheath Tumors are not a Feature of Neurofibromatosis Type 2 in the Unirradiated Patient. Neurosurgery. 83(1). 38–42. 20 indexed citations

11.

Halliday, Dorothy, Pieter Pretorius, Samuel MacKeith, et al.. (2017). Genetic Severity Score predicts clinical phenotype in NF2. Journal of Medical Genetics. 54(10). 657–664. 93 indexed citations

12.

Morris, Katrina, John F. Golding, Patrick Axon, et al.. (2016). Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncology Practice. 3(4). 281–289. 59 indexed citations

13.

Morris, Katrina, John F. Golding, Claire Blesing, et al.. (2016). Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. Journal of Neuro-Oncology. 131(1). 117–124. 40 indexed citations

14.

Morris, Katrina, Allyson Parry, & Pieter Pretorius. (2016). Comparing the sensitivity of linear and volumetric MRI measurements to detect changes in the size of vestibular schwannomas in patients with neurofibromatosis type 2 on bevacizumab treatment. British Journal of Radiology. 89(1065). 20160110–20160110. 10 indexed citations

15.

Jones, Adrian L., Harry Joe, Miriam J. Smith, et al.. (2015). Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. Journal of Medical Genetics. 52(10). 699–705. 63 indexed citations

16.

Ferner, Rosalie E., Adam Shaw, D. Gareth Evans, et al.. (2014). Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. Journal of Neurology. 261(5). 963–969. 36 indexed citations

17.

Mistry, Niraj, et al.. (2009). Thunderclap headache. Practical Neurology. 9(5). 294–297. 1 indexed citations

18.

Korteweg, T., Mar Tintoré, Bernard M.J. Uitdehaag, et al.. (2009). A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome. European Radiology. 19(9). 2244–2248. 4 indexed citations

19.

Korteweg, Tijmen, Mar Tintoré, Bernard M.J. Uitdehaag, et al.. (2006). MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. The Lancet Neurology. 5(3). 221–227. 101 indexed citations

20.

Morgan, Rhian, Allyson Parry, Ricardo Mário Arida, et al.. (2006). Effects of elevated plasma tryptophan on brain activation associated with the Stroop task. Psychopharmacology. 190(3). 383–389. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact